Investornewsbreaks - Senestech Inc.'S (NASDAQ: SNES) Contrapest(R) Delivers Significant Benefits In Efficacy Studies


(MENAFN- Investor Brand Network) SenesTech (NASDAQ: SNES) , an animal pest control innovator, created its own unique niche within the pest control market after introducing its non-lethal liquid ContraPest(R) bait.“Instead of poisoning rats, the bait targets fertility reduction in male and female rats, and Evolve(TM) has a similar mechanism of action but in a soft bait presentation preferred over liquids by pest management professionals ('PMPs') and residential customers. SenesTech's products are the first, and still the only, such rat contraceptives for both males and females registered with the U.S. Environmental Protection Agency ('EPA') designed to be non-lethal,” a recent article explains.“The company conducted studies of ContraPest's effectiveness at poultry farms on the east and west coasts of the United States, through the farms' integrated pest management programs. The studies showed that SenesTech's product cut the rat population in half in three months and produced a sustained 90% reduction over the 12-month study at the western facility, and that pullet survival from predation rebounded by 88% at the eastern facility – delivering hundreds of thousands of dollars in benefits in the process.”

To view the full article, visit

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to SNES are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Los Angeles, CA

310.299.1717 Office
...

InvestorWire is powered by
IBN

MENAFN01032024000224011066ID1107923453


Investor Brand Network

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.